Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you consider switching capmatinib to tepotinib or vice versa due to grade 3 hepatotoxicity in a patient with metastatic NSCLC with MET Exon 14 skipping mutation?
Related Questions
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
When should a biopsy be obtained to rule out small cell transformation in a patient with stage IV NSCLC and an EGFR mutation?
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Is there any data supporting the use of osimertinib in patients with L858R-mutated lung cancer who had a durable response to prior EGFR TKI therapy, and who progressed 1-2 years after discontinuation of other EGFR inhibitors?
For a patient with NSCLC harboring an EGFR or ALK mutation that transforms into SCLC, would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Would you add immunotherapy to chemotherapy for a patient with metastatic NSCLC, an atypical EGFR mutation, and PD-L1 ≥50% who has progressed on osimertinib?
Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
How do you approach duration of immunotherapy in patients with metastatic NSCLC?
